ATHENS, Greece, Sept. 08, 2026 (GLOBE NEWSWIRE) — Dynagas LNG Partners LP (NYSE: DLNG) (the “Partnership”), an owner of liquefied natural gas (“LNG”) carriers, today announced its results for the three and six months ended June 30, 2026. Half year Highlights:Net Income and Earnings per common unit (basic and diluted) of $33.4 million and $0.82, respectively; Adjusted Net Income(1) of $28.2 million and Adjusted Earnings per common unit(1) (basic and diluted) of $0.68; Adjusted EBITDA(1) of $51.9 million; and 95.7% fleet utilization(2).Quarter Highlights:Net Income and Earnings per common unit (basic and diluted) of $16.0 million and $0.39, respectively; Adjusted Net Income(1) of $15.8 million and Adjusted Earnings per common unit(1) (basic and diluted) of $0.39; Adjusted EBITDA(1) of $27.6 million; 96.2% fleet utilization(2); The...

Company Anticipates $7M-$8M FY’26 Adjusted Gross Profit(1), vs. Prior Guidance $5M-$7M Company Anticipates Adjusted Net Operating Cash Flow(4) to Turn Positive in Q3’26 Company Anticipates Generating Positive Core Operating Earnings(3) in Q3’26 Company Announces New $20M Stock Buyback Authorization DALLAS, Sept. 08, 2026 (GLOBE NEWSWIRE) — Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), the first U.S. publicly listed DeFi company building on Hyperliquid, today raised its full-year 2026 guidance and provided new Q3’26 guidance driven by its core operations exceeding management’s prior expectations. In addition, the Company is launching a new $20 million share buyback program. “In the past few weeks, our DeFi businesses have accelerated,” said Hyunsu Jung, CEO of Hyperion DeFi. Mr. Jung continued, “We have now...

RAMAT GAN, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) — Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced clinical updates and financial results for H1 2026. Advances in Clinical Programs Pancreatic Cancer Phase 2a study evaluating Namodenoson in patients with advanced pancreatic ductal adenocarcinoma achieved its primary safety endpoint and demonstrated durable overall survival outcomes. The open-label Phase IIa study enrolled 20 patients with advanced pancreatic ductal adenocarcinoma who had progressed following standard therapies. Fourteen patients received Namodenoson as third-line treatment, five as second-line treatment, and one as fourth-line treatment. Namodenoson was well...

Raises Midpoint of Outlook For Fiscal 2026 Adjusted EPS and Increases Free Cash Flow ExpectationsRevenue increased 4.2% to a quarterly record of $2.3 billion, including organic growth of 2.1% and acquisition-related growth of 2.1% Net income increased 19% to $49.7 million, or $0.84 per diluted share, as compared to $41.8 million, or $0.67, in the prior year Adjusted net income grew 19% to $61.5 million, or $1.04 per diluted share, versus $51.7 million, or $0.82, in the prior year Adjusted EBITDA improved 11% to $139.6 million, versus $125.8 million last year Operating cash flow was $146.8 million and free cash flow totaled $128.4 million Through nine months, operating cash flow was $275.0 million and free cash flow was $199.6 million, both significantly improved over the prior year period Company raises outlook for full year adjusted...

Paris, 8 September 2026, 9.00am Rubis announces today that its half-year financial report as of 30 June 2026 is available and has been filed with the Autorité des Marchés Financiers (the French Financial Markets Authority – AMF). The 2026 half-year financial report can be downloaded from Rubis’ website (www.rubis.fr), in the “Investors – Regulated information – Half-year financial report” section.    This document is a translation of the original French document and is provided for information purposes only. In all matters of interpretation of information, views or opinions expressed therein, the original French version takes precedence over this translation  Contact  RUBIS – Legal Department  Tel: +(33) 1 44 17 95 95AttachmentRubis: Availability of the 2026 half-year financial report

 Paris, 08 September 2026, 7:00amEBITDA at €434m, +18% yoy reflecting sustained demand, disciplined execution and optimised inventory management in a volatile and high oil price context, highlighting the Group’s ability to consistently deliver strong results across challenging market conditions. Net income Group share of €191m, +17% yoy in line with operational performance. Cash flow generation – Adjusted cash flow from operating activities1 at €223m in H1 2026 (vs €276m in H1 2025) reflecting higher working capital requirements amid higher oil prices. Corporate Net Financial Debt to EBITDA ratio2 of 1.3x at Jun-2026 vs 1.4x in H1 2025, confirming the robustness of Rubis balance sheet – Total Net Financial Debt3 of €1,466m. 2026 EBITDA guidance upgraded to €775m to €825m (previously €740m-€790m) underpinned by strong first-half...

PRESS RELEASE Bloomberg (THEON:NA) / Reuters (THEON.AS)07 September 2026 – Theon International Plc (THEON) is pleased to announce the publication of its H1 2026 Report for the six months ended 30 June 2026 which is now available on the IR website. This follows the H1 2026 Trading Update published on 27 July 2026, with the key financials reiterated. The Company is holding a live webcast for analysts and investors tomorrow (08 September 2026) at 3:00 PM EEST (1:00 PM BST). The webcast details are accessible here. H1 2026 Overview As previously announced, H1 2026 performance was characterised by strong revenue growth (35.4%), industry-leading profitability (Adjusted EBIT margin 26.2%), a sustained book-to-bill ratio of c 1.0x, and significant expansion of THEON’s addressable market to nearly €8 billion due to expansion into high-growth...

Press ReleaseAvailability of the 2026 half-year Financial Report Reims, September 7th 2026 MAISON POMMERY & ASSOCIES has filed today its 2026 half-year Financial Report with the French Autorité des Marchés Financiers (AMF). It is available to the public under the conditions set out in the regulations in force and can be downloaded from the Group’s website in the Investor Relations / Press Releases and Regulated Information section at the following address: https://www.maisonpommery.com/en/type-presse/financial-reports/ Maison Pommery & Associés is a major player in the Champagne sector. The Group controls the entire value chain, from vine cultivation to wine production and marketing. The Group also has a presence in three other wine regions (Provence, Camargue, and Douro). It is strongly committed to promoting terroirs,...

Financial Press ReleaseFirst-half 2026 results Commercial momentum driven by Champagne Pommery & GrenoConsolidated turnover of €96.2m i.e. +0.7% on a like-for-like basis1 (-12.0% as reported), including +7.1% for Champagne Pommery & Greno Net income of -€4.0m, down €2.5m, a direct consequence of the disposal of Heidsieck & Co Monopole, not fully offset over the half-year Reduction in net financial debt and Group financing secured until June 2027, with a possible extension to 2028Reims, September 7, 2026 The Board of Directors of Maison Pommery & Associés met on September 7, 2026 under the chairmanship of Mrs. Nathalie Vranken, and in the presence of the Statutory Auditors, notably to approve the Group’s consolidated financial statements for the first half of 2026. The limited review procedures on the half-year financial...

INDIANAPOLIS, Sept. 04, 2026 (GLOBE NEWSWIRE) — Hurco Companies, Inc. (Nasdaq: HURC) today reported results for the third fiscal quarter ended July 31, 2026. Hurco recorded net income of $2,314,000, or $0.35 per diluted share, for the third quarter of fiscal year 2026, compared to a net loss of $3,693,000, or $(0.58) per diluted share, for the corresponding period in fiscal year 2025. For the first nine months of fiscal year 2026, Hurco reported a net loss of $3,526,000, or $(0.55) per diluted share, compared to a net loss of $12,076,000, or $(1.87) per diluted share, for the corresponding period in fiscal year 2025. Sales and service fees for the third quarter of fiscal year 2026 were $47,289,000, an increase of $1,483,000, or 3%, compared to the corresponding prior year period, and included an unfavorable currency impact of $20,000,...